Basaglar
- PMID: 28761222
- PMCID: PMC5510923
- DOI: 10.2337/cd017-0025
Basaglar
References
-
- Basaglar [prescribing information] Indianapolis, Ind., Eli Lilly/Boehringer Ingelheim, 2016
-
- Truven Health Analytics Micromedex Solutions [Internet]. Available from http://www.micromedexsolutions.com/micromedex2/librarian/CS/8685A3/ND_PR.... Accessed 1 March 2017
-
- Peters AL, Pollom RD, Zielonka JS, Carey MA, Edelman SV. Biosimilars and new insulin versions. Endocr Pract 2015;21:1387–1394 - PubMed
-
- U.S. Food and Drug Administration FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes. Available from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm. Accessed 1 March 2017
-
- Blevins TC, Dahl D, Rosenstock J, et al. . Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomised controlled trial (the ELEMENT 1 study). Diabetes Obes Metab 2015;17:726–733 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources